Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schweiger, M; Wasler, A; Prenner, G; Stiegler, P; Stadlbauer, V; Schwarz, M; Tscheliessnigg, K.
Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Transpl Immunol. 2006; 16(1): 46-51.
Doi: 10.1016/j.trim.2006.02.001
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Schweiger Martin
- Co-Autor*innen der Med Uni Graz
- Andrä Michaela
- Prenner Günther
- Stadlbauer-Köllner Vanessa
- Stiegler Philipp
- Tscheliessnigg Karlheinz
- Wasler Andrae
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Long-term survival of patients after oHTX significantly increased over the last years, but CAV and chronic renal failure due to nephrotoxic side-effects of CNIs still remain unsolved problems. Everolimus has shown to reduce acute cellular rejection and may allow CsA dosage reduction. In this study the effectiveness of Everolimus in combination with CsA dosage reduction in maintenance oHTX immunosuppression and the influence on renal function was tested. METHODS: 37 patients (30 male, 7 female) after oHTX were divided into group A (n = 20) receiving Everolimus in combination with CsA and prednisolone and group B (n = 17) under standard immunosuppression with CsA, MMF and prednisolone. Patients received 1.0 mg to 1.5 mg Everolimus per day and target Everolimus trough levels were between 3 and 8 ng/ml. Death, safety, side effects, BPAR, trough levels, and routine laboratory values especially creatinine levels were monitored over a follow-up period of 8 months retrospectively and statistically evaluated. RESULTS: A significant reduction of CsA dosage (p < 0.001) and a significant CsA trough level reduction (p < 0.001) to a median CsA trough level of 68.5 ng/ml were achieved in group A. Mean Everolimus trough levels were reached within 1 week and 2 months. Renal function was stable in both groups. No statistical differences in BPAR, hospitalization rates or triglyceride levels were observed. Cholesterol levels significantly increased in group B (p = 0.024). CONCLUSION: CsA trough levels and dosage can be significantly reduced in combination with Everolimus without higher rejection rates and with stable kidney function in oHTX patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Cyclosporine - adverse effects Cyclosporine - blood Cyclosporine - therapeutic use
- Dose-Response Relationship, Drug -
- Drug Administration Schedule -
- Drug Therapy, Combination -
- Female -
- Graft Rejection - physiopathology Graft Rejection - prevention and control
- Heart Transplantation - immunology
- Humans -
- Immunosuppressive Agents - adverse effects Immunosuppressive Agents - blood Immunosuppressive Agents - therapeutic use
- Kidney Function Tests -
- Male -
- Middle Aged -
- Retrospective Studies -
- Sirolimus - adverse effects Sirolimus - analogs and derivatives Sirolimus - blood Sirolimus - therapeutic use
- Find related publications in this database (Keywords)
- cardiac transplantation
- everolimus
- immunosuppression
- rejection
- cyclosporine A